"Morgan Joseph initiates INCY with a Buy and $8 tgt. They note that the co's lead product candidate, DFC, is currently in Phase IIb development as a once-daily oral therapy for HIV. They anticipate positive results from this study, which should become available in 1H07. They also believe the co's CCR2 program, recently partnered with Pfizer (PFE), could translate into substantial revenues in the form of milestones and royalties.They believe newsflow from other internal programs, including novel sheddase inhibitors for cancer (currently in Phase I/II dose-ranging studies) and an oral CCR5 antagonist for HIV (Phase I slated to begin in 1H06), will boost investor interest."
December 2005 January 2006 February 2006 March 2006 April 2006 May 2006 July 2006 August 2006 October 2006 November 2006 December 2006 January 2007 February 2007 March 2007 April 2007 May 2007 June 2007 August 2007 October 2007 November 2007 May 2008 September 2008 October 2008 January 2009 February 2009 March 2009 April 2009 May 2009 June 2009 July 2009 August 2009 September 2009 October 2009 November 2009 December 2009 March 2010 May 2010 June 2010Great Investments Blog   Great Investment Articles Blog
Disclaimer: Great Trades may have a position in all or some of the stocks discussed in this blog, but is not paid by any company to promote their stock. Great Trades contains opinions, none of which constitute a recommendation that any particular security, transaction, or investment strategy is suitable for any specific person. Great Trades does not provide personalized investment advice.